VEOS: Comparison of a Speech-Language Assessment Tool for Pragmatic and Discourse Skills in Schizophrenia Spectrum Disorders

Sponsor
Centre Hospitalier Universitaire de Nice (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05742893
Collaborator
(none)
30
1
8

Study Details

Study Description

Brief Summary

The scientific literature has largely objectified language disorders in schizophrenia. And more precisely, the impairment of pragmatic and discursive language skills. Currently, there is no standardized language assessment tool specific to these patients. The aim of this study is to compare the effectiveness of a newly developed speech-language assessment tool for pragmatic and discourse skills for patients suffering from schizophrenia .

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Measurement of pragmatic and discourse test scores in the two scales.
N/A

Detailed Description

The scientific literature has largely objectified language disorders in schizophrenia. And more precisely, the impairment of pragmatic and discursive language skills. Currently, there is no standardized language assessment tool specific to these patients. The aim of this study is to compare the effectiveness of a newly developed speech-language assessment tool for pragmatic and discourse skills for patients suffering from schizophrenia.

To do so, patients will have to pass six tests: three tests of the new tool and three corresponding gold standard tests. The first two tests will assess pragmatic skills by means of a semi-directed interview. The next two tests will assess discourse skills through two image description tasks. Finally, the last two tests will evaluate narrative skills through the oral restitution of two heard texts.

The main objective is to compare the performance of schizophrenic patients detected in the pathological zone with the scales of the new tool versus the gold standard scales.

The secondary objective is to determine which skills are most affected by comparing patients' scores in pragmatic skills versus those in discourse skills.

This tool would allow to precisely objectify language disorders and to optimize the multidisciplinary diagnosis and care of patients suffering from schizophrenia.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
30 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Comparison of a Speech-Language Pathology Assessment Tool for Pragmatic and Discourse Skills for Patients With Schizophrenic Spectrum Disorders and Other Psychotic Disorders
Anticipated Study Start Date :
Mar 1, 2023
Anticipated Primary Completion Date :
Oct 31, 2023
Anticipated Study Completion Date :
Oct 31, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: diagnostic

all patients have the study test

Diagnostic Test: Measurement of pragmatic and discourse test scores in the two scales.
The aim of this study is to compare the effectiveness of a newly developed speech-language assessment tool for pragmatic and discourse skills for patients suffering from schizophrenia .

Outcome Measures

Primary Outcome Measures

  1. assess of pragmatic skills [day 0]

    The patients is evaluated by means of a semi-directed interview

  2. assess discourse skills [day 0]

    he patient is evaluated through two image description tasks

  3. assess narrative skills [day 0]

    the patients is evaluated through the oral restitution of two heard texts.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 99 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Male or female between the ages of 18 and 60

  • Patient with a diagnosis of schizophrenic spectrum disorder and other psychotic disorders meeting DSM V criteria

  • Patient who has been clinically and treatment stable for at least three months

  • Patient who can read and write French

  • Patient who is a beneficiary of a social security plan or similar

  • Patient with ability to sign free and informed consent

Exclusion Criteria:
    • Patient hospitalized under restraint
  • Patient under guardianship

  • Patient who has stopped taking his or her treatment

  • Patient who had a change in treatment in the period of less than three months prior to the pass

  • Patient with a worsening of the disease in the three months prior to the inclusion visit

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Centre Hospitalier Universitaire de Nice

Investigators

  • Principal Investigator: Benoit Michel, Centre Hospitalier Universitaire de Nice

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Centre Hospitalier Universitaire de Nice
ClinicalTrials.gov Identifier:
NCT05742893
Other Study ID Numbers:
  • 22-AOI-04
First Posted:
Feb 24, 2023
Last Update Posted:
Feb 24, 2023
Last Verified:
Jan 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 24, 2023